Pharmacology and neuroprotective properties of rasagiline
Rasagiline [R(+)-N-propargyl-1-aminoindane] is a selective irreversible inhibitor of MAO-B which is not metabolised to amphetamine-like derivatives. Like deprenyl, when given to rats in a dose selective for inhibition of MAO-B, it does not affect striatal extracellular fluid dopamine levels, but when administered chronically (21 days) it increased striatal microdialysate dopamine without reduction in deaminated metabolites. Similarly to deprenyl, rasagiline (10-6M) increased the percentage of tyrosine hydroxylase positive cells in a primary culture of rat fetal mesencephalic cells (6 days in culture). Rasagiline, but not deprenyl, also increased the number of neurons per field in this organotypic culture.
KeywordsTyrosine Hydroxylase Monoamine Oxidase Prop Argyl Dopaminergic Cell Microdialysis Probe
Unable to display preview. Download preview PDF.
- Colzi A, d’Agostini F, Kettler R, Borroni E, Da Prada M (1990) Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study. J Neural Transm [Suppl] 32: 79–84Google Scholar
- Finberg JPM, Tenne M, Youdim MBH (1981b) Selective irreversible propargyl derivative inhibitors of monoamine oxidase (MAO) without the cheese effect. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors — the state of the art. Wiley, Chichester, pp 31–43Google Scholar
- Kalir A, Sabbagh A, Youdim MBH (1981) Selective acetylenic “suicide” and reversible inhibitors of monoamine oxidase type A and B. Br J Pharmacal 73: 55–64Google Scholar
- Knoll J (1986) The pharmacology of (−)deprenyl. J Neural Transm [Suppl] 22: 75–89Google Scholar
- Knoll J (1992) (−)Deprenyl medication: a strategy to modulate the age-related decline of the striatal dopaminergic system. J Am Geriatr Soc 40: 839–847 ai]Kuroki T, Tsutsumi T, Hirano M, Matsumoto T, Tatebayashi Y, Nishiyama K, Uchimura H, Shiraishi A, Nakahara T, Nakamura K (1990) Behavioral sensitization to betaphenylethylamine (PEA): enduring modifications of specific dopaminergic neuron systems in the rat. Psychopharmacol 102: 5–10PubMedGoogle Scholar
- Lees A, Kohout L, Shaw JK, Stern G, Elsworth JD, Sandler M, Youdim MBH (1977) Deprenyl in Parkinson’s disease. Lancet 2: 791–795Google Scholar
- Riederer P, Konradi C, Schay V, Kienzel E, Youdim MBH (1986) Location of MAO A and MAO B in human brain. A step in understanding the thepeutic action of 1-deprenyl. Adv Neurol 45: 111–119Google Scholar
- Tatton WG (1993) Selegiline can mediate neuronal rescue rather than neuronal protection. Mov Disord 8 [Suppl] 1: 20–30Google Scholar
- Tekes K, Tothfalusi L, Gaal J, Magyar K (1988) Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain. Pol J Pharmacol 40: 653–658Google Scholar